Beckwith-Wiedemann Syndrome is a genetic growth disorder that is usually present at birth. It is characterized by low blood sugar at birth, abdominal organs that stick out of the belly button, and a higher likelihood of tumors or cancers. The symptoms of Beckwith-Wiedemann Syndrome include enlarged organs, prominent eyes, and seizures. Treatment for Beckwith-Wiedemann Syndrome usually includes surgical repair of the abdominal organs and treatment of the blood sugar. Once the person has survived childhood, the outlook is good, but tumors are still likely.
Beckwith-wiedemann Syndrome Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Beckwith-wiedemann Syndrome below!
For more information on how to use Laverne, please read the How to Guide.
We have 1080 products for the study of Beckwith-wiedemann Syndrome that can be applied to Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry, Chromatin Immunoprecipitation (ChIP) from our catalog of antibodies and ELISA kits.
Beckwith-wiedemann Syndrome is also known as beckwith-wiedemann syndrome, wiedemann-beckwith syndrome (wbs), emg syndrome, exomphalos macroglossia gigantism syndrome, exomphalos-macroglossia-gigantism syndrome.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.